Table 1.
Summary of trials on front-line treatments including TKI
Im indicates imatinib; Das, dasatinib; Nil, nilotinib; Pon, ponatinib; and n.a., not available.
* Elderly population.
† Published as an abstract.
Summary of trials on front-line treatments including TKI
Im indicates imatinib; Das, dasatinib; Nil, nilotinib; Pon, ponatinib; and n.a., not available.
* Elderly population.
† Published as an abstract.
